Reinventing the ACE inhibitors: Some old and new implications of ACE inhibition

Hypertension Research

Volumn 33, Issue 1, 2010, Pages 11-21

  Hanif, Kashif ^a   Bid, Hemant K ^a   Konwar, Rituraj ^a  

^a CENTRAL DRUG RESEARCH INSTITUTE   (India)

Author keywords

ACE inhibitors; Blood pressure; Bradykinin; Cancer; Memory

Indexed keywords

2 ETHYL 5,7 DIMETHYL 3 [4 [2 (2H TETRAZOL 5 YL)PHENYL]BENZYL]IMIDAZO[4,5 B]PYRIDINE; AMLODIPINE; ANGIOTENSIN 1 RECEPTOR ANTAGONIST; ANTIHYPERTENSIVE AGENT; BENAZEPRIL; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM ANTAGONIST; CAPTOPRIL; DIPEPTIDYL CARBOXYPEPTIDASE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; ENALAPRIL; ENKEPHALINASE INHIBITOR; FOSINOPRIL; INDAPAMIDE; LISINOPRIL; LOSARTAN; MOEXIPRIL; NIFEDIPINE; OMAPATRILAT; PERINDOPRIL; PLACEBO; QUINAPRIL; RAMIPRIL; RXP 407; SERASPENIDE; THIAZIDE DIURETIC AGENT; TRANDOLAPRIL; UNCLASSIFIED DRUG; UNINDEXED DRUG; ZOFENOPRIL;

ACUTE HEART INFARCTION; ANGIONEUROTIC EDEMA; ANTIHYPERTENSIVE ACTIVITY; ANTINEOPLASTIC ACTIVITY; ANTINOCICEPTION; ANTIOXIDANT ACTIVITY; ATHEROSCLEROSIS; ATHEROSCLEROTIC PLAQUE; CARDIOTOXICITY; CEREBROVASCULAR ACCIDENT; CLINICAL TRIAL; COGNITIVE DEFECT; CONGESTIVE HEART FAILURE; COUGHING; DIABETIC NEPHROPATHY; DIABETIC NEUROPATHY; DRUG ACTIVITY; DRUG FATALITY; DRUG POTENCY; DRUG STRUCTURE; ENZYME ACTIVITY; ENZYME INHIBITION; ESSENTIAL HYPERTENSION; EXFOLIATIVE DERMATITIS; FACE EDEMA; HEART FAILURE; HEART INFARCTION; HEART LEFT VENTRICLE FAILURE; HEART LEFT VENTRICLE HYPERTROPHY; HEART PROTECTION; HEART RATE; HEART VENTRICLE HYPERTROPHY; HUMAN; HYPERKALEMIA; HYPERTENSION; HYPOTENSION; INTRAUTERINE GROWTH RETARDATION; ISCHEMIC HEART DISEASE; JOINT CONTRACTURE; KIDNEY ARTERY STENOSIS; KIDNEY CANCER; KIDNEY DYSFUNCTION; KIDNEY FAILURE; LUNG HYPOPLASIA; MACULOPAPULAR RASH; MEMORY ENHANCING EFFECT; MOUTH EDEMA; NEOPLASM; NEPHROTIC SYNDROME; NEUROLOGIC DISEASE; NEUROPROTECTION; NEUTROPENIA; NONHUMAN; NOSE EDEMA; OLIGOHYDRAMNIOS; PAIN; PROTEIN FUNCTION; RASH; REVIEW; SIDE EFFECT; SYSTOLIC HEART FAILURE; TACHYCARDIA; TONGUE SWELLING; VASCULAR ENDOTHELIUM;

ANGIOTENSIN II TYPE 1 RECEPTOR BLOCKERS; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; ANIMALS; ANTINEOPLASTIC AGENTS; CARDIOVASCULAR DISEASES; HUMANS; MEMORY; PEPTIDYL-DIPEPTIDASE A; RENIN-ANGIOTENSIN SYSTEM;

EID: 74349085543     PISSN: 09169636     EISSN: 13484214     Source Type: Journal    
DOI: 10.1038/hr.2009.184     Document Type: Review

References (203)

1. Levy D, Larson MG, Vasan RS, Kannel WB, Ho KKL. The progression from hypertension to congestive heart failure. JAMA 1996; 275: 1557-1562. (Pubitemid 26154241)
2. http://www.mayoclinic.com/health/high-blood-pressure/HI00062.
3. Lonn E, Gerstein HC, Smieja M, Mann JFE, Yusuf S. Mechanisms of cardiovascular risk reductions with ramipril: insights from HOPE and HOPE substudies. Eur Heart J 2003; 5(Suppl A): A43-A48.
4. Bicket DP. Using ACE inhibitors appropriately. Am Fam Physician 2002; 66: 461-468.
5. Skidgel RA, Erdos E. Biochemistry of angiotensin I-converting enzyme. In: Robertson JIS, Nicholls MG (eds). The Renin-Angiotensin System. Raven Press Ltd: New York, 1993. pp 1.01-10.10.
6. Brown NJ, Vaughan DE. Angiotensin-converting enzyme inhibitors. Circulation 1998; 97: 1411-1420.
7. Chobian AV, Barkis GL, Black HR, Cushman WC, Green LA, Izzo Jr JL, Jones DW, Materson BJ, Oparil S, Wright Jr JT, Roccella EJ. The seventh report of the joint national committee on prevention, detection, evaluation and treatment of high blood pressure. JAMA 2003; 289: 2560-2571.
8. ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group. The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial. Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: the Anti-hypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). JAMA 2002; 288: 2981-2997.
9. Vidt DG, Bravo EL, Fouad FM. Medical intelligence therapy: captopril. N Engl J Med 1982; 306: 214-219.
10. Todd PA, Heel RC. Enalapril: a review of its pharmacodynamic and pharmacokinetic properties and therapeutic use in hypertension and congestive heart failure. Drugs 1986; 31: 198-248.
11. Pool JL, Gennari J, Goldstein R, Kochar MS, Lewin AJ, Maxwell MH, McChesney JA, Mehta J, Nash DT, Nelson EB, Rastogi S, Rofman B, Weinberger M. Controlled multicenter study of antihypertensive effects of lisinopril, hydrochlorothiazide, and lisinopril plus hydrochlorothiazide in the treatment of 394 patients with mild to moderate essential hypertension. J Cardiovasc Pharmacol 1987; 3: S36-S42.
12. Case DB, Atlas SA, Laragh JH, Sullivan PA, Sealey JE. Use of first-dose response or plasma renin activity to predict the long-term effect of captopril: identification of triphasic pattern of blood pressure response. J Cardiovasc Pharmacol 1980; 2: 339-346.
13. Given BD, Taylor T, Hollenberg NK, Williams GH. Duration of action and short-term hormonal responses to enalapril (MK-421) in normal subjects. J Cardiovasc Pharmacol 1984; 6: 436-441.
14. Waeber B, Gavras I, Brunner HR, Cook CA, Charocopos F, Gavras HP. Prediction of sustained antihypertensive efficacy of chronic captopril therapy: relationships to immediate blood pressure response and control plasma renin activity. Am Heart J 1982; 103: 384-390.
15. Waeber B, Brunner HR, Brunner DB, Curtet AL, Turini CA, Gavras H. Discrepancy between antihypertensive effect and angiotensin converting enzyme inhibition by captopril. Hypertension 1980; 2: 236-242. (Pubitemid 10010507)
16. Veterans Administration Co-operative Study Group of Antihypertensive Agents. Racial differences in response to low-dose captopril are abolished by the addition of hydrochlorothiazide. Br J Clin Pharmacol 1982; 14: 97S-101S.
17. Lund-Johansen P, Omvik P. Long-term haemodynamic effects of enalapril (alone and in combination with hydrochlorothiazide) at rest and during exercise in essential hypertension. J Hypertens 1984; 2: S49-S50.
18. Ibsen H, Egan B, Osterzeil K, Vander A, Julius S. Reflex-hemodynamic adjustments and baroreflex sensitivity during converting enzyme inhibition with MK-421 in normal humans. Hypertension 1983; 5(Suppl I): I-184-I-189.
19. Dunn GF, Oigman W, Ventura HO, Messerli FH, Kobrin I, Frolich ED. Enalapril improves systemic and renal hemodynamics and allows regression of left ventricular mass in essential hypertension. Am J Cardiol 1984; 53: 105-108.
20. Simon AC, Levenson JA, Bouthier J, Maarek B, Safar ME. Effects of acute and chronic angiotensin enzyme inhibition on large arteries in human hypertension. J Cardiovasc Pharmacol 1985; 7: S45-S51.
21. Dusing R, Kayser G, Wagner S, Scherf H, Glanzer K, Predel HG, Kramer HJ. Baroreflex setting and sensitivity in normal subjects: effects of pharmacologic inhibition of the angiotensin I converting enzyme. Am J Cardiol 1987; 59: 50D-54D.
22. Guidicelli JF, Berdeaux A, Edouard A, Richer C, Jacolot D. The effect of enalapril on baroreceptor mediated reflex function in normotensive subjects. Br J Clin Pharmacol 1985; 20: 211-218.
23. Ajayi AA, Campbell BC, Meredith PA, Kelman AW, Reid JL. The effect of captopril on the reflex control heart rate: possible mechanisms. Br J Clin Pharmacol 1985; 20: 17-25.
24. Giannattasio C, Grassi G, Seravalle G, Morganti A, Zanchetti A, Mancia G. Investigation of reflexes from volume and baroreceptors during converting-enzyme inhibition in humans. Am Heart J 1989; 117: 740-745.
25. Uchiyama-Tanaka Y, Mori Y, Kishimoto N, Fukui M, Nose A, Kijima Y, Yamahara H, Hasegawa T, Kosaki A, Matsubara H, Iwasaka T. Comparison of the effects of quinapril and losartan on carotid artery intima-media thickness in patients with mild-to-moderate arterial hypertension. Kidney Blood Press Res 2005; 28: 111-116.
26. Hayek T, Keidar S, Mei-Y, Oiknine J, Breslow J. Effect of angiotensin converting enzyme inhibitors on LDL lipid peroxidation and atherosclerosis progression in apo E deficient mice. Circulation 1995; 92(Suppl I): I-625.
27. Chobanian AV, Haudenschild CC, Nickerson C, Drago R. Antiatherogenic effect of captopril in the Watanabe heritable hyperlipidemic rabbit. Hypertension 1990; 15: 327-331.
28. Aberg G, Ferrer P. Effects of captopril on atherosclerosis in cynomolgus monkeys. J Cardiovasc Pharmacol 1990; 15(suppl 5): S65-S72.
29. Morawietz H, Rueckschloss U, Niemann B, Duerrschmidt N, Galle J, Hakim K, Zerkowski HR, Sawamura T, Holtz J. Angiotensin II induces LOX-1, the human endothelial receptor for oxidized low-density lipoprotein. Circulation 1999; 100: 899-902.
30. Mancini GB, Henry GC, Macaya C, O'Neill BJ, Pucillo AL, Carere RG, Wargovisch TJ, Mudra H, Luscher TF, Klibaner MI, Haber HE, Uprichard AC, Pepine CJ, Pitt B. Angiotensin-converting enzyme inhibition with quinapril improves endothelial vaso-motor dysfunction in patients with coronary artery disease: the TREND (Trial on Reversing Endothelial Dysfunction) Study. Circulation 1996; 94: 258-265.
31. Linz W, Wiemer G, Gohlke P, Unger T, Scholkens BA. Contribution of kinins to the cardiovascular actions of angiotensin-converting enzyme inhibitors. Pharmacol Rev 1995; 47: 25-49.
32. Vaughan DE, Lazos SA, Tong K. Angiotensin II regulates the expression of plasminogen activator inhibitor-1 in cultured endothelial cells. J Clin Invest 1995; 95: 995-1001.
33. Ridker PM, Gaboury CL, Conlin PR, Seely EW, Williams GH, Vaughan DE. Stimulation of plasminogen activator inhibitor in vivo by infusion of angiotensin II. Circulation 1993; 87: 1969-1973.
34. Emeis JJ, Tranquille N. On the role of bradykinin in secretion from vascular endothelial cells. Agents Actions 1992; 38: 285-291.
35. Brown NJ, Nadeau J, Vaughan DE. Selective stimulation of tissue-type plasminogen activator (t-PA) in vivo by infusion of bradykinin. Thromb Haemost 1997; 77: 522-525.
36. The Heart Outcomes Prevention Evaluation Study Investigators. Effects of an angio-tensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. N Engl J Med 2000; 342: 145-153.
37. de Nigris F, D'Armiento FP, Somma P, Casini A, Andreini I, Sarlo F, Mansueto G, De Rosa G, Bonaduce D, Condorelli M, Napoli C. Chronic treatment with sulfhydryl angiotensin-converting enzyme inhibitors reduce susceptibility of plasma LDL to in vitro oxidation, formation of oxidation-specific epitopes in the arterial wall, and atherogenesis in apolipoprotein E knockout mice. Int J Cardiol 2001; 81: 107-115.
38. CONSENSUS Trial Study Group. Effects of enalapril on mortality in severe congestive heart failure: results of the Cooperative North Scandinavian Enalapril Survival Study (CONSENSUS). N Engl J Med 1987; 316: 1429-1435.
39. The SOLVD Investigators. Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure. N Engl J Med 1991; 325: 293-302.
40. Cohn JN, Johnson G, Ziesche J, Frederick C, Francis G, Tristani F, Smith R, Dunkman WB, Loeb H, Wong M, Bhat G, Goldman S, Fletcher RD, Doherty J, Hughes CV, Carson P, Cintron G, Shabetai R, Haakenson C. A comparison of enalapril with hydralazine-isosorbidedinitrate in the treatment of chronic congestive heart failure. N Engl J Med 1991; 325: 303-310.
41. AIRE Study Group. Effect of ramipril on mortality and morbidity of survivors of acute myocardial infarction with clinical evidence of heart failure. Lancet 1993; 342: 821-828.
42. Kober L, Torp-Pederson C, Carlsen JE, Bagger H, Eliasen P, Lyngborg K, Videbaek J, Cole DS, Auclert L, Pauly NC, Aliot E, Persson S, Camm AJ. For the Trandolapril Cardiac Evaluation (TRACE) Study Group. A clinical trial of the angiotensin-convert-ing-enzyme inhibitor trandolapril in patients with left ventricular dysfunction after myocardial infarction. N Engl J Med 1995; 333: 1670-1676.
43. Pfeffer MA, Braunwald EA, Moye LA, Basta L, Brown EJJ, Cuddy TE, Davis BR, Geltman EM, Goldman S, Flaker GC, Klein M, Lamas GA, Packer M, Rouleau J, Rouleau JL, Rutherford J, Wertheimer JH, Hawkins CM. Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction. N Engl J Med 1992; 327: 669-677.
44. Yusuf S, Pepine CJ, Garces C, Pouleur H, Salem D, Kostis J, Benedict C, Rousseau M, Bourassa M, Pitt B. Effect of enalapril on myocardial infarction and unstable angina in patients with low ejection fractions. Lancet 1992; 340: 1173-1178.
45. Vaughan DE, Pfeffer MA. Angiotensin converting enzyme inhibitors and cardiovascular remodelling. Cardiovasc Res 1994; 28: 159-165.
46. Dahlof B. Effect of angiotensin II a blockade on cardiac hypertrophy and remodelling: a review. J Hum Hypertens 1995; 9(suppl 5): S37-S44.
47. Nakashima Y, Fouad FM, Tarazi RC. Regression of left ventricular hypertrophy from systemic hypertension by enalapril. Am J Cardiol 1994; 53: 1044-1049.
48. Gaudio C, Tanzilli G, Collatina S, Pagnotta P, Paknejad K, Campa PP. Evaluation of regression of left ventricular hypertrophy in hypertensive patients treated with captopril as assessed by magnetic resonance imaging. Cardiologia 1992; 37: 789-791.
49. Schmieder RE, Martus P, Klingbeil A. Reversal of left ventricular hypertrophy in essential hypertension: meta-analysis of randomized double-blind studies. JAMA 1996; 275: 1507-1513.
50. Givertz MM. Manipulation of the renin-angiotensin system. Circulation 2001; 104: e14-e18.
51. ACE Inhibitor Myocardial Infarction Collaborative Group. Indications for ACE inhibitors in the early treatment of acute myocardial infarction: systematic overview of individual data from 100 000 patients in randomized trials. Circulation 1998; 97: 2202-2212.
52. J S. Angiotensin-converting enzyme inhibition: a landmark advance in treatment for cardiovascular diseases. Eur Heart J Suppl 2007; 9 (Supplement E): E2-E9.
53. Ferrari R. Effects of angiotensin-converting enzyme inhibition with perindopril on left ventricular remodeling and clinical outcome: results of the randomized Perindopril and Remodeling in Elderly with Acute Myocardial Infarction (PREAMI) Study. Arch Intern Med 2006; 166: 659-666.
54. Ryan TJ, Antman EM, Brooks NH, Califf RM, Hillis LD, Hiratzka LF, Rapaport E, Riegel B, Russell RO, Smith 3rd EE, Weaver WD, Gibbons RJ, Alpert JS, Eagle KA, Gardner TJ, Garson Jr A, Gregoratos G, Smith Jr SC. 1999 update: ACC/AHA guidelines for the management of patients with acute myocardial infarction: executive summary and recommendations: a report of the American college of cardiology/ American heart association task force on practice guidelines (committee on management of acute myocardial infarction). Circulation 1999; 100: 1016-1030. (Pubitemid 29407188)
55. Yusuf S, Sleight P, Pogue J, Bosch J, Davies R, Dagenais G. Effects of an angiotensin-converting enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients: the Heart Outcomes Prevention Evaluation Study Investigators. N Engl J Med 2000; 342: 145-153.
56. Ichikawa I, Brenner BM. Glomerular actions of angiotensin II. Am J Med 1984; 76: 43-49.
57. Fogo A, Yoshida Y, Yared A, Ichikawa I. Importance of angiogenic action of angiotensin II in the glomerular growth of maturing kidneys. Kidney Int 1990; 38: 1068-1074.
58. Ruiz-Ortega M, Gomez-Garre D, Alcazar R, Palacios I, Bustos C, Gonzalez S, Plaza JJ, Gonzalez E, Egido J. Involvement of angiotensin II and endothelin in matrix protein production and renal sclerosis. J Hypertens 1994; 12: S51-S58.
59. Anderson SG, Rennke HG, Brenner BM. Therapeutic advantage of converting enzyme inhibitors in arresting progressive renal disease associated with systemic hypertension in rat. J Clin Invest 1986; 77: 1993-2000.
60. Hoelscher DD, Weir MR, Bakris GL. Hypertension in diabetic patients: an update of interventional studies to preserve renal function. J Clin Pharmacol 1995; 35: 73-80.
61. Ravid M, Lang R, Rachmani R, Lishner M. Long-term renoprotective effect of angiotensin-converting enzyme inhibition in non-insulin dependent diabetes mellitus: a 7-year follow-up study. Arch Intern Med 1996; 156: 286-289.
62. Lewis EJ, Hunsicker LG, Bain RP, Rohde RD. The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy. N Engl J Med 1993; 329: 1456-1462.
63. Maschio G, Alberti D, Janin G, Locatelli F, Mann JF, Motolese M, Ponticelli C, Ritz E, Zucchelli P. Effect of the angiotensin-converting enzyme inhibitor benazepril on the progression of chronic renal insufficiency: the Angiotensin-Converting-Enzyme Inhibition in Progressive Renal Insufficiency Study Group. N Engl J Med 1996; 334: 939-945.
64. Amann B, Tinzmann R, Angelkort B. ACE Inhibitors improve diabetic nephropathy through suppression of renal MCP-1. Diabetes Care 2003; 26: 2421-2425.
65. Seshiah PN, Weber DS, Rocic P, Valppu L, Taniyama Y, Griendling KK. Angiotensin II stimulation of NAD(P)H oxidase activity. Circ Res 2002; 91: 406-413.
66. Mollnau H, Wendt M, Szocs K, Lassegue B, Schulz E, Oelze M, Li H, Bodenschatz M, August M, Kleschyov AL, Tsilimingas N, Walter U, Forstermann U, Meinertz T, Griendling K, Munzel T. Effects of angiotensin II infusion on the expression and function of NAD(P)H oxidase and components of nitric oxide/cGMP signaling. Circ Res 2002; 90: E58-E65.
67. Wang HD, Xu S, Johns DG, Du Y, Quinn MT, Cayatte AJ, Cohen R. Role of NADPH oxidase in the vascular hypertrophic and oxidative stress response to angiotensin II in mice. Circ Res 2001; 88: 947-953.
68. Escobales N, Crespo MJ. Oxidative-nitrosative stress in hypertension (Review). Curr Vasc Pharmacol 2005; 3: 231-246.
69. Cotter MA, Cameron NE. Effect of the NAD(P)H oxidase inhibitor, apocynin, on peripheral nerve perfusion and function in diabetic rats. Life Sci 2003; 73: 1813-1824.
70. Aggarwal M, Singh J, Sood S, Arora B. Effects of lisinopril on streptozotocin-induced diabetic neuropathy in rats. Methods Find Exp Clin Pharamacol 2001; 23: 131-134.
71. Malik RA, Williamson S, Abbott C, Carrington AL, Iqbal J, Schady W, Boulton AJ. Effect of angiotensin-converting-enzyme (ACE) inhibitor trandolapril on human diabetic neuropathy: randomized double-blind controlled trial. Lancet 1998; 352: 1978-1981.
72. Reja A, Tesfaye S, Harris ND, Ward JD. Is ACE inhibition with lisinopril helpful in diabetic neuropathy? Diabet Med 1995; 12: 307-309.
73. Terata K, Coppey LJ, Davidson EP, Dunlap JA, Gutterman DD, Yorek MA. Acetylcho-line-induced arteriolar dilation is reduced in streptozotocin (STZ)-induced diabetic rats with motor nerve dysfunction. Br J Pharmacol 1999; 128: 837-843.
74. Yorek MA, Coppey LJ, Gellett JS, Davidson EP. Sensory nerve innervations of epineurial arterioles of the sciatic nerve containing calcitonin gene related peptide: effect of streptozotocin-induced diabetes. Exp Diabesity Res 2004; 5: 187-193.
75. Coppey LJ, Gellett JS, Davidson EP, Yorek MA. Preventing superoxide formation in epineurial arterioles of the sciatic nerve from diabetic rats restores endothelium-dependent vasodilation. Free Radical Res 2003; 37: 33-40.
76. Coppey LJ, Gellett JS, Yorek MA. Mediation of vascular relaxation in epineurial arterioles of the sciatic nerve: effect of diabetes in type 1 and type 2 diabetic rat models. Endothelium 2003; 10: 89-94.
77. Coppey L, Gellett J, Davidson E, Dunlap J, Lund D, Yorek M. Effect of antioxidant treatment of streptozotocin-induced diabetic rats on endoneurial blood flow, motor nerve conduction velocity, and vascular reactivity of epineurial arterioles of the sciatic nerve. Diabetes 2001; 50: 1927-1937. (Pubitemid 33641615)
78. Coppey LJ, Davidson EP, Rinehart TW, Gellett JS, Oltman CL, Lund DD, Yorek MA. ACE inhibitor or angiotensin II receptor antagonist attenuates diabetic neuropathy in streptozotocin-induced diabetic rats. Diabetes 2006; 55: 341-348.
79. O'Driscoll G, Green D, Rankin J, Stanton K, Taylor R. Improvement in endothelial function by angiotensin converting enzyme inhibition in insulin-dependent diabetes mellitus. J Clin Invest 1997; 100: 678-684.
80. Malik RA, Schofield IJ, Izzard A, Austin C, Bermann G, Heagerty AM. Effects of angiotensin type-1 receptor antagonism on small artery function in patients with type 2 diabetes mellitus. Hypertension 2005; 45: 264-269.
81. Goto K, Fujii K, Kansui Y, Iida M. Changes in endothelium-derived hyperpolarizing factor in hypertension and ageing: response to chronic treatment with rennin-angiotensin system inhibitors. Clin Exp Pharmacol Physiol 2004; 31: 650-655.
82. Kihara M, Mitsui MK, Mitsui Y, Okuda K, Nakasaka Y, Takahashi M, Schmelzer JD. Altered vasoreactivity to angiotensin II in experimental diabetic neuropathy: role of nitric oxide. Muscle Nerve 1999; 22: 920-925.
83. Griendling KK, Sorescu D, Ushio-Fukai M. NAD (P) H oxidase: role in cardiovascular biology and disease. Circ Res 2000; 86: 494-501.
84. Griendling KK, Minieri CA, Ollerenshaw JD, Alexander RW. Angiotensin II stimulates NADH and NADPH oxidase activity in cultured vascular smooth muscle cells. Circ Res 1994; 74: 1141-1148.
85. Laursen JB, Rajagopalan S, Galis Z, Tarpey M, Freeman BA, Harrison DG. Role of superoxide in angiotensin II-induced but not catecholamine-induced hypertension. Circulation 1997; 95: 588-593.
86. 2 in angiotensin II-induced vascular hypertrophy. Hypertension 1998; 32: 488-495.
87. Warnholtz A, Nickenig G, Schulz E, Macharzina R, Bräsen JH, Skatchkov M, Heitzer T, Stasch JP, Griendling KK, Harrison DG, Böhm M, Meinertz T, Münzel T. Increased NADH oxidase-mediated superoxide production in the early stages of atherosclerosis: evidence for involvement of the renin-angiotensin system. Circulation 1999; 99: 2027-2033.
88. Münzel T, Keaney JF. Are ACE inhibitors a 'Magic Bullet' against oxidative stress? Circulation 2001; 104: 1571.
89. Mancini GB, Henry GC, Macaya C, O'Neill BJ, Pucillo AL, Carere RG, Wargovich TJ, Mudra H, Lüscher TF, Klibaner MI, Haber HE, Uprichard AC, Pepine CJ, Pitt B. Angiotensin-converting enzyme inhibition with quinapril improves endothelial vaso-motor dysfunction in patients with coronary artery disease: the TREND (Trial on Reversing Endothelial Dysfunction) Study. Circulation 1996; 94: 258-265.
90. Wiemer G, Linz W, Hatrik S, Schölkens BA, Malinski T. Angiotensin-converting enzyme inhibition alters nitric oxide and superoxide release in normotensive and hypertensive rats. Hypertension 1997; 30: 1183-1190.
91. Lonn E, Yusuf S, Dzavik V, Doris C, Yi Q, Smith S, Moore-Cox A, Bosch J, Riley W, Teo K, SECURE Investigators. Effects of ramipril and vitamin E on atherosclerosis: the study to evaluate carotid ultrasound changes in patients treated with ramipril and vitamin E (SECURE). Circulation 2001; 103: 919-925.
92. Napoli C, Cicala C, D'Armiento FP, Roviezzo F, Somma P, de Nigris F, Zuliani P, Bucci M, Aleotti L, Casini A, Franconi F, Cirino G. Beneficial effects of ACE-inhibition with zofenopril on plaque formation and low-density lipoprotein oxidation in watanabe heritable hyperlipidemic rabbits. Gen Pharmacol 1999; 33: 467-477. (Pubitemid 30047152)
93. Fernandes AC, Filipe PM, Freitas JP, Manso CF. Different effects of thiol and nonthiol ACE inhibitors on copper-induced lipid and protein oxidative modification. Free Radic Biol Med 1996; 20: 507-514.
94. Kim JA, Gu JL, Natarajan R, Berliner JA, Nadler JL. A leukocyte type of 12-lipoxygenase is expressed in human vascular and mononuclear cells. Evidence for upregulation by angiotensin II. Arterioscler Thromb Vasc Biol 1995; 15: 942-948.
95. Scheidegger KJ, Butler S, Witztum JL. Angiotensin II increases macrophage-mediated modification of low density lipoprotein via a lipoxygenase-dependent pathway. J Biol Chem 1997; 272: 21609-21615.
96. Keidar S, Kaplan M, Hoffman A, Aviram M. Angiotensin II stimulates macrophage-mediated oxidation of low density lipoproteins. Atherosclerosis 1995; 115: 201-215.
97. Parthasarathy S, Wieland E, Steinberg D. A role for endothelial cell lipoxygenase in the oxidative modification of low density lipoprotein. Proc Natl Acad Sci USA 1989; 86: 1046-1050.
98. Dohi Y, Hahn AWA, Boulanger CM, Buhler FR, Luscher TF. Endothelin stimulated by angiotensin II augments contractility of spontaneously hypertensive rat resistance arteries. Hypertension 1992; 19: 131-137.
99. Luscher TF, Boulanger CM, Dohi Y, Yang Z. Endothelium derived contracting factors. Hypertension 1992; 19: 117-130.
100. Turlapaty PDMV, Altura BM. Magnesium deficiency produces spasms of the coronary arteries: relationships to etiology of sudden ischemic heart disease. Science 1980; 208: 198-200.
101. Eisenberg MJ. Magnesium deficiency and sudden death. Am Heart J 1992; 124: 544-549.
102. Sapna S, Ranjith SK, Shivakumar K. Cardiac fibrogenesis in magnesium deficiency: a role for circulating angiotensin II and aldosterone. Am J Physiol Heart Circ Physiol 2006; 291: H436-H440.
103. Mogielnicki A, Chabielska E, Pawlak R, Szemraj J, Buczko W. Angiotensin II enhances thrombosis development in renovascular hypertensive rats. Thromb Haemost 2005; 93: 1069-1076.
104. Ambrose JA, Martinez EE. A new paradigm for plaque stabilization. Circulation 2002; 105: 2000-2004.
105. Barbagallo M, Dominguez LJ, Resnick LM. Protective effects of captopril against ischemic stress. Hypertension 1999; 34: 958-963.
106. Amenta F, Mignini F, Rabbia F, Tomassoni D, Veglio F. Protective effect of anti-hypertensive treatment on cognitive function in essential hypertension: analysis of published clinical data. J Neurol Sci 2002; 203-204: 147-151.
107. Manschot SM, Biessels GJ, Cameron NE, Cotter MA, Kamal A, Kappelle LJ, Gispen WH. Angiotensin converting enzyme inhibition partially prevents deficits in water maze performance, hippocampal synaptic plasticity and cerebral blood flow in streptozotocin-diabetic rats. Brain Res 2003; 966: 274-282.
108. Wyss JM, Kadish I, van Groen T. Age-related decline in spatial learning and memory: attenuation by captopril. Clin Exp Hypertens 2003; 25: 455-474.
109. PROGRESS Collaborative Group. Randomised trial of a perindopril-based blood-pressure-lowering regimen among 6105 individuals with previous stroke or transient ischaemic attack. Lancet 2001; 358: 1033-1041.
110. Skidgel RA, Defendini R, Erdos EG. Angiotensin I converting enzyme and its role in neuropeptide metabolism. In Turner AJ (ed). Neuropeptides and their peptidases. Ellis Horwood Ltd: Chichester, UK, 1987. pp 165-182.
111. Hasenohrl RU, Souza-Silv AMA, Nikolaus S, Tomaz C, Brandao ML, Schwarting RK, Huston JP. Substance P and its role in neural mechanisms governing learning, anxiety and functional recovery. Neuropeptides 2000; 34: 272-280.
112. Oitzl MS, Hasenohrl RU, Huston JP. Reinforcing effects of peripherally administered substance P and its C-terminal sequence pGlu6-SP6-11 in the rat. Psychopharma-cology (Berl) 1990; 100: 308-315.
113. Shirayama Y, Mitsushio H, Takashima M, Ichikawa H, Takahashi K. Reduction of substance P after chronic antidepressants treatment in the striatum, substantia nigra and amygdala of the rat. Brain Res 1996; 739: 70-78.
114. Tomaz C, Silva AC, Nogueira PJ. Long-lasting mnemotropic effect of substance P and its N-terminal fragment (SP1-7) on avoidance learning. Braz J Med Biol Res 1997; 30: 231-233.
115. Ukai M, Kobayashi T, Kameyama T. Dynorphin A-(1-13) attenuates basal forebrain-lesion-induced amnesia in rats. Brain Res 1993; 625: 355-356.
116. Hiramatsu M, Watanabe E. Dynorphin A (2-13) improves mecamylamine-induced learning impairment accompanied by reversal of reductions in acetylcholine release in rats. Neuropeptides 2006; 40: 47-56.
117. Hiramatsu M, Mori H, Murasawa H, Kameyama T. Improvement by dynorphin A (1-13) of galanin-induced impairment of memory accompanied by blockade of reductions in acetylcholine release in rats. Br J Pharmacol 1996; 118: 255-260.
118. Gold PE. Coordination of multiple memory systems. Neurobiol Learn Mem 2004; 82: 230-242.
119. Gold PE. Acetylcholine modulation of neural systems involved in learning and memory. Neurobiol Learn Mem 2003; 80: 194-210.
120. Ager EI, Neo J, Christophi C. The renin-angiotensin system and malignancy. Carci-nogenesis 2008; 29: 1675-1684.
121. Deshayes F, Nahmias C. Angiotensin receptors: a new role in cancer? Trends Endocrinol Metab 2005; 16: 293-299.
122. Escobar E, Rodríguez-Reyna TS, Arrieta O, Sotelo J. Angiotensin II, cell proliferation and angiogenesis regulator: biologic and therapeutic implications in cancer. Curr Vasc Pharmacol 2004; 2: 385-399.
123. Uemura H, Ishiguro H, Kubota Y. Angiotensin II receptor blocker: possibility of antitumor agent for prostate cancer. Mini Rev Med Chem 2006; 6: 835-844.
124. Zhao Y, Chen X, Cai L, Yang Y, Sui G, Wu J. Angiotensin II suppresses adriamycin-induced apoptosis through activation of phosphatidylinositol 3-kinase/Akt signaling in human breast cancer cells. Acta Biochim Biophys Sin (Shanghai) 2008; 40: 304-310.
125. Ohashi H, Takagi H, Oh H, Suzuma K, Suzuma I, Miyamoto N, Uemura A, Watanabe D, Murakami T, Sugaya T, Fukamizu A, Honda Y. Phosphatidylinositol 3-kinase/Akt regulates angiotensin II-induced inhibition of apoptosis in microvascular endothelial cells by governing survivin expression and suppression of caspase-3 activity. Circ Res 2004; 94: 785-793.
126. Puddefoot JR, Udeozo UKI, Barker S, Vinson GP. The role of angiotensin II in the regulation of breast cancer cell adhesion and invasion. Endocr Relat Cancer 2006; 13: 895-903.
127. Ribatti D, Conconi MT, Nussdorfer GG. Nonclassic endogenous novel regulators of angiogenesis. Pharmacol Rev 2007; 59: 185-205.
128. Fujita M, Hayashi I, Yamashina S, Fukamizu A, Itoman M, Majima M. Angiotensin type 1a receptor signaling-dependent induction of vascular endothelial growth factor in stroma is relevant to tumor-associated angiogenesis and tumor growth. Carcinog-enesis 2005; 26: 271-279.
129. Suzuki Y, Ruiz-Ortega M, Lorenzo O, Ruperez M, Esteban V, Egido J. Inflammation and angiotensin II. Int J Biochem Cell Biol 2003; 35: 881-900.
130. El Bekay R, Alvarez M, Monteseirín J, Alba G, Chacón P, Vega A, Martin-Nieto J, Jiménez J, Pintado E, Bedoya FJ, Sobrino F. Oxidative stress is a critical mediator of the angiotensin II signal in human neutrophils: involvement of mitogen activated protein kinase, calcineurin, and the transcription factor NF-kB. Blood 2003; 102: 662-671.
131. Hii SI, Nicol DL, Gotley DC, Thompson LC, Green MK, Jonsson JR. Captopril inhibits tumour growth in a xenograft model of human renal cell carcinoma. Br J Cancer 1998; 77: 880-883.
132. Volpert OV, Ward WF, Lingen MW, Chesler L, Solt DB, Johnson MD, Molteni A, Polverini PJ, Bouck NP. Captopril inhibits angiogenesis and slows the growth of experimental tumors in rats. J Clin Invest 1996; 98: 671-679.
133. Yoshiji H, Kuriyama S, Kawata M, Yoshii J, Ikenaka Y, Noguchi R, Nakatani T, Tsujinoue H, Fukui H. ACE inhibitor perindopril significantly inhibits tumor growth and angiogenesis along with suppression of the VEGF level. Clin Cancer Res 2001; 7: 1073-1078.
134. Lindberg H, Nielsen D, Jensen BV, Eriksen J, Skovsgaard T. Angiotensin converting enzyme inhibitors for cancer treatment? Acta Oncol 2004; 43: 142-152.
135. Williams RN, Parsons S, Rowlands B, Watson S. Novel inhibition of matrix metallo-proteinases, angiogenesis, and tumour cell invasion by captopril. Gastroenterology 2003; 124: A603.
136. Williams RN, Parsons SL, Morris TM, Rowlands BJ, Watson SA. Inhibition of matrix metalloproteinase activity and growth of gastric adenocarcinoma cells by an angio-tensin converting enzyme inhibitor in in vitro and murine models. Eur J Surg Oncol 2005; 31: 1042-1050.
137. de Groot-Besseling RR, Ruers TJ, van Kraats AA, Poelen GJ, Ruiter DJ, de Waal RM, Westphal JR. Anti-tumor activity of a combination of plasminogen activator and captopril in a human melanoma xenograft model. Int J Cancer 2004; 112: 329-334.
138. McMurray J, Chopra M. Influence of ACE inhibitors on free radicals and reperfusion injury: pharmacological curiosity or therapeutic hope? Br J Clin Pharmacol 1991; 31: 373-379.
139. Wysocki PJ, Kwiatkowska EP, Kazimierczak U, Suchorska W, Kowalczyk DW, Mack-iewicz A. Captopril, an angiotensin-converting enzyme inhibitor, promotes growth of immunogenic tumors in mice. Clin Cancer Res 2006; 12: 4095-4102.
140. Friis S, Sørensen HT, Mellemkjaer L, McLaughlin JK, Nielsen GL, Blot WJ, Olsen JH. Angiotensin-converting enzyme inhibitors and the risk of cancer: a population-based cohort study in Denmark. Cancer 2001; 92: 2462-7240.
141. Meier CR. Angiotensin-converting enzyme inhibitors, calcium channel blockers, and breast cancer. Arch Intern Med 2000; 160: 349-355.
142. Grossman E, Messerli FH, Goldbourt U. Antihypertensive therapy and the risk of malignancies. Eur Heart J 2001; 22: 1343-1352.
143. Lever AF, Hole DJ, Gillis CR, McCallum IR, McInnes GT, MacKinnon PL, Meredith PA, Murray LS, Reid JL, Robertson JW. Do inhibitors of angiotensin-converting enzyme protect against risk of cancer? Lancet 1998; 352: 179-184.
144. Silber JH, Cnaan A, Clark BJ, Paridon SM, Chin AJ, Rychik J, Hogarty AN, Cohen MI, Barber G, Rutkowski M, Kimball TR, Delaat C, Steinherz LJ, Zhao H. Enalapril to prevent cardiac function decline in long-term survivors of pediatric cancer exposed to anthracyclines. J Clin Oncol 2004; 22: 820-822.
145. Medeiros R, Vasconcelos A, Costa S, Pinto D, Lobo F, Morais A, Oliveira J, Lopes C. Linkage of angiotensin I-converting enzyme gene insertion/deletion polymorphism to the progression of human prostate cancer. J Pathol 2004; 202: 330-335. (Pubitemid 38325242)
146. Rocken C, Lendecke U, Dierkes J, Westphal S, Carl-McGrath S, Peters B, Kruger S, Malfertheiner P, Roessner A, Ebert MPA. The number of lymph node metastases in gastric cancer correlates with the angiotensin I converting enzyme gene insertion/ deletion polymorphism. Clin Cancer Res 2005; 11: 2526-2530.
147. Ebert MP, Lendeckel U, Westphal S, Dierkes J, Glas J, Folwaczny C, Roessner A, Stolte M, Malfertheiner P, Röcken C. The Angiotensin I-converting enzyme gene insertion/deletion polymorphism is linked to early gastric cancer. Cancer Epidemiol Biomarkers Prev 2005; 14: 2987-2989.
148. Grand AM, Maresca AM. Blockade of the renin-angiotensin-aldosterone system: effects on hypertensive target organ damage. Cardiovasc Hematolo Agents Med Chem 2006; 4: 219-228.
149. Brilla CG, Janicki JS, Weber KT. Impaired diastolic function and coronary reserve in genetic hypertension. Role of interstitial fibrosis and medial thickening of intramyo-cardial coronary arteries. Circ Res 1991; 69: 107.
150. Anderson S, Rennke HG, Brenner BM. Therapeutic advantage of converting enzyme inhibitors in arresting progressive renal disease associated with systemic hypertension in the rat. J Clin Invest 1986; 77: 1993-2000.
151. Maschio G, Alberti D, Janin G, Locatelli F, Mann JF, Motolese M, Ponticelli C, Ritz E, Zucchelli P. Effect of the angiotensin-converting-enzyme inhibitor benazepril on the progression of chronic renal insufficiency. N Engl J Med 1996; 334: 939-945.
152. Schachinger V, Britten MB, Zeiher AM. Prognostic impact of coronary vasodilator dysfunction on adverse long-term outcome of coronary heart disease. Circulation 2000; 101: 1899-1906.
153. Ghiadoni L, Magagna A, Versari D, Kardasz I, Huang Y, Taddei S, Salvetti A. Different effect of antihypertensive drugs on conduit artery endothelial function. Hypertension 2003; 41: 1281-1286.
154. Hecker M, Blaukat A, Bara AT, Müller-Esterl W, Busse R. ACE inhibitor potentiation of bradykinin-induced venoconstriction. Br J Pharmacol 1997; 121: 1475-1481.
155. Hecker M, Pörsti I, Bara AT, Busse R. Potentiation by ACE inhibitors of the dilator response to bradykinin in the coronary microcirculation: interaction at the receptor level. Br J Pharmacol 1994; 111: 238-244.
156. Minshall RD, Erdös EG, Vogel SM. Angiotensin I-converting enzyme inhibitors potentiate bradykinin's inotropic effects independently of blocking its inactivation. Am J Cardiol 1997; 80: 132A-136A.
157. 2 receptors and angiotensin I-converting enzyme in CHO cells. Circ Res 1997; 81: 848-856.
158. 1 receptor by ACE inhibitors. Int Immunopharmacol 2002; 2: 1787-1793. (Pubitemid 35375260)
159. Kohlstedt K, Busse R, Fleming I. Signaling via the angiotensin-converting enzyme enhances the expression of cyclooxygenase-2 in endothelial cells. Hypertension 2005; 45: 126-132.
160. Kohlstedt K, Shoghi F, Müller-Esterl W, Busse R, Fleming I. CK2 phosphorylates the angiotensin-converting enzyme and regulates its retention in the endothelial cell plasma membrane. Circ Res 2002; 91: 749-756.
161. Irvine RJ, White JM, Head RJ. The renin angiotensin system and nociception in spontaneously hypertensive rats. Life Sci 1995; 56: 1073-1078.
162. Ghione S. Hypertension-associated hypalgesia: evidence in experimental animals and humans, pathophysiological mechanisms, and potential clinical consequences. Hypertension 1996; 28: 494-504.
163. Takai S, Song K, Tanaka T, Okunishi H, Miyazaki M. Antinociceptive effects of angiotensin-converting enzyme inhibitors and an angiotensin II receptor antagonist in mice. Life Sci 1996; 59: PL331-PL336.
164. Guasti L, Grimoldi P, Diolisi A, Petrozzino MR, Gaudio G, Grandi AM, Rossi MG, Venco A. Treatment with enalapril modifies the pain perception pattern in hypertensive patients. Hypertension 1998; 31: 1146-1150.
165. Kalra J, Chaturvedi A, Kalra S, Chaturvedi H, Dhasmana DC. Modulation of pain perception by ramipril and losartan in human volunteers. Indian J Physiol Pharmacol 2008; 52: 91-96.
166. Brunton L, Parker K, Blumenthal D, Buxton I (eds). Renin and angiotensin. Goodman & Gillman's Manual of Pharmacology and Therapeutics. McGraw Hill: New York, 2008. pp 511-527.
167. Warren SE, O'Connor DT. Hyperkalemia resulting from captopril administration. JAMA 1980; 244: 2551-2552.
168. Textor SC, Bravo EL, Fouad FM, Tarazi RC. Hyperkalemia in azotemic patients during angiotensin-converting enzyme inhibition and aldosterone reduction with captopril. Am J Med 1982; 73: 719-725.
169. Burnakis TG, Mioduch HJ. Combined therapy with captopril and potassium supplementation: a potential for hyperkalemia. Arch Int Med 1984; 144: 2371-2372.
170. Dzau VJ. Renal effects of angiotensin-converting enzyme inhibition in cardiac failure. Am J Kidney Dis 1987; 10: 74-80.
171. Murphy BF, Whitworth JA, Kincaid-Smith P. Renal insufficiency with combinations of angiotensin converting enzyme inhibitors and diuretics. Br Med J Clin Res 1984; 288: 844-845.
172. Kastner PR, Hall JE, Guyton AC. Control of glomerular filtration rate: role of intrarenally formed angiotensin II. Am J Physiol 1984; 246: F897-F906.
173. Israili ZH, Hall WD. Cough and angioneurotic edema associated with angiotensin-converting enzyme inhibitor therapy. Ann Intern Med 1992; 117: 234-242.
174. Friedman JM. ACE inhibitors and congenital anomalies. N Engl J Med 2006; 354: 2498-2500.
175. DiBianco R. Adverse reactions with angiotensin converting enzyme inhibitors. Med Toxicol 1986; 1: 122-141.
176. Marin-Castaño ME, Schanstra JP, Neau E, Praddaude F, Pecher C, Ader JL, Girolami JP, Bascands JL. Induction of functional bradykinin b (1)-receptors in normotensive rats and mice under chronic Angiotensin-converting enzyme inhibitor treatment. Circulation 2002; 105: 627-632.
177. Blood Pressure Lowering Treatment Trialists' Collaboration, Turnbull F, Neal B, Pfeffer M, Kostis J, Algert C, Woodward M, Chalmers J, Zanchetti A, MacMahon S. Blood pressure-dependent and independent effects of agents that inhibit the renin-angiotensin system. J Hypertens 2007; 25: 951-958.
178. Strauss MH, Hall AS. Angiotensin receptor blockers may increase risk of myocardial infarction: unraveling the ARB-MI paradox. Circulation 2006; 114: 838-854.
179. Groth W, Blume A, Gohlke P, Unger T, Culman J. Chronic pretreatment with candesartan improves recovery from focal cerebral ischaemia in rats. J Hypertens 2003; 21: 2175-2182.
180. Li J, Culman J, Hortnagl H, Zhao Y, Gerova N, Timm M, Blume A, Zimmermann M, Seidel K, Dirnagl U, Unger T. Angiotensin AT2 receptor protects against cerebral ischemia-induced neuronal injury. FASEB J 2005; 19: 617-619.
181. Sigmund CD, Davisson RL. Targeting brain AT1 receptors by RNA interference. Hypertension 2006; 47: 145-146.
182. Fournier A, Messerli FH, Achard JM, Fernandez L. Cerebroprotection mediated by angiotensin II: a hypothesis supported by recent randomized clinical trials. J Am Coll Cardiol 2004; 43: 1343-1347.
183. McMurray JJ. ACE inhibitors in cardiovascular disease-unbeatable? N Engl J Med 2008; 358: 1615-1616.
184. Weber MA. Vasopeptidase inhibitors. Lancet 2001; 358: 1525-1532.
185. Coats AJS. Omapatrilat-the story of OVERTURE and OCTAVE. Int J Cardiol 2002; 86: 1-4.
186. Zanchi A, Maillard M, Burnier M. Recent clinical trials with omapatrilat: new developments. Curr Hypertens Rep 2003; 5: 346-352.
187. Cugno M, Nussberger J, Cicardi M, Agostoni A. Bradykinin and the pathophysiology of angioedema. Int Immunopharmacol 2003; 3: 311-317.
188. Campbell DJ. Vasopeptidase inhibition. A double-edged sword? Hypertension 2003; 41: 383-389.
189. Junot C, Gonzales MF, Ezan E, Cotton J, Vazeux G, Michaud A, Azizi M, Vassiliou S, Yiotakis A, Corvol P, Dive V. RXP 407, a selective inhibitor of the N-domain of angiotensin I-converting enzyme, blocks in vivo the degradation of hemoregulatory peptide acetyl-Ser-Asp-Lys-Pro with no effect on angiotensin I hydrolysis. J Pharmacol Exp Ther 2001; 297: 606-611.
190. Geordiadis D, Beau F, Czarny B, Cotton J, Yiotakis A, Dive V. Roles of the two active sites of somatic angiotensin-converting enzyme in the cleavage of angiotensin I and bradykinin. Circ Res 2003; 93: 148-154.
191. Messerli FH, Nussberger J. Vasopeptidase inhibition and angioedema. Lancet 2000; 356: 608-609.
192. Tom B, de Vries R, Saxena PR, Danser AHJ. Bradykinin potentiation by angiotensin-(1-7) and ACE inhibitors correlates with ACE C-and N-domain blockade. Hypertension 2001; 38: 95-99.
193. Rousseau A, Michaud A, Chauvet MT, Lenfant M, Corvol P. The hemoregulatory peptide N-acetyl-Ser-Asp-Lys-Pro is a natural and specific substrate of the N-terminal active site of human angiotensin-converting enzyme. J Biol Chem 1995; 270: 3656-3661.
194. Ehlers MRW, Riordan JF. Angiotensin-converting enzyme: zinc-and inhibitor-binding stoichiometries of the somatic and testis isozymes. Biochemistry 1991; 30: 7118-7126.
195. Deddish PA, Marcic B, Jackman HL, Wang HZ, Skidgel RA, Erdös EG. N-domain-specific substrate and C-domain inhibitors of angiotensin-converting enzyme: Angio-tensin-(1-7) and keto-ACE. Hypertension 1998; 31: 912-917.
196. Azizi M, Junot C, Ezan E, Menard J. Angiotensin I-converting enzyme and metabolism of the haematological peptide N-acetyl-seryl-aspartyl-lysyl-proline. Clin Exp Pharmacol Physiol 2001; 28: 1066-1069.
197. Rhaleb NE, Peng H, Harding P, Tayeh M, LaPointe MC, Carretero OA. Effect of N-acetyl-seryl-aspartyl-lysylproline on DNA and collagen synthesis in rat cardiac fibroblasts. Hypertension 2001; 37: 827-832.
198. Menard J, Patchett AA. Angiotensin-converting enzyme inhibitors. Adv Prot Chem 2001; 56: 13-75.
199. Wei L, Clauser E, Alhenc-Gelas F, Corvol P. The two homologous domains of human angiotensin I-converting enzyme interact differently with competitive inhibitors. J Biol Chem 1992; 267: 13398-13405.
200. Cotton J, Hayashi MA, Cuniasse P, Vazeux G, Ianzer D, De Camargo AC, Dive V. Selective inhibition of the C-domain of angiotensin I converting enzyme by bradykinin potentiating peptides. Biochemistry 2002; 41: 6065-6071.
201. Hayashi MA, Murbach AF, Ianzer D, Portaro FC, Prezoto BC, Fernandes BL, Silveira PF, Silva CA, Pires RS, Britto LR, Dive V, Camargo AC. The C-type natriuretic peptide precursor of snake brain contains highly specific inhibitors of the angiotensin-converting enzyme. J Neurochem 2003; 85: 969-977.
202. Dive V, Cotton J, Yiotakis A, Michaud A, Vassiliou S, Jiracek J, Vazeux G, Chauvet MT, Cuniasse P, Corvol P. RXP 407, a phosphinic peptide, is a potent inhibitor of angiotensin I converting enzyme able to differentiate between its two active sites. Proc Natl Acad Sci USA 1999; 96: 4330-4335.
203. Acharya KR, Sturrock ED, Riordan JF, Ehlers MR. ACE revisited: a new target for structure-based drug design. Nat Rev Drug Discov 2003; 2: 891-902.